Lopez, Federico G.

HRN: 212186  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/06/2022
CEFTRIAXONE 1G (VIAL)
04/06/2022
04/12/2022
IVT
2gms
Once A Day
Hepatic Mass, Benign Vs Malignant, Cannot Totally Rule Out Ameobic Abscess
Waiting Final Action 
04/06/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/06/2022
04/15/2022
IV
500mg
Every 8hrs
Hepatic Mass, Benign Vs Malignant Cannot Totally Rule Out Ameobic Abscess
Waiting Final Action 
04/10/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/10/2022
04/16/2022
IVT
750mg
Every 8 Hours
8hrs Hepatic Mass, Benign Vs Malignant Cannot Totally Rule Out Ameobic Abscess
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: